As illustrated in Figure 3, BCG therapy not only enhances PD-L1 expression on BC cells but also reshapes the tumor immune microenvironment by recruiting immune cells and activating adaptive immune responses, thereby offering a complementary mechanism to ICIs. Here, CD274 is linked to breast cancer.